BIIB•benzinga•
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
Summary
UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 20, 2024 by benzinga